NCT06580002
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Recruiting · Phase 2 · University of California, Irvine · registry updated 2026-07-14
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.
Inclusion
- Cohort-specific inclusion for male and female patients.
- a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:
- Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions.
- Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.
- Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.
- b. Cohort B (prior cranial radiation)
Exclusion
- Cohort-specific exclusion for male and female patients:
- Cohort A (no prior cranial radiation)
- History of or current presence of primary brain tumors or brain metastases.
- Cohort B (prior cranial radiation)
- Diagnosed with high grade glioma.
- Unwilling to undergo neuropsychological assessments necessary for the study.